{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T16:14:51Z","timestamp":1759421691500,"version":"3.37.3"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2021,2,12]],"date-time":"2021-02-12T00:00:00Z","timestamp":1613088000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,2,12]],"date-time":"2021-02-12T00:00:00Z","timestamp":1613088000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Rheumatol"],"published-print":{"date-parts":[[2021,9]]},"DOI":"10.1007\/s10067-021-05622-w","type":"journal-article","created":{"date-parts":[[2021,2,12]],"date-time":"2021-02-12T12:04:20Z","timestamp":1613131460000},"page":"3499-3510","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Does current evidence on disease-modifying antirheumatic drugs for psoriatic arthritis reinforce an effect on radiographic progression? Results from a systematic review and meta-analysis"],"prefix":"10.1007","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6778-5119","authenticated-orcid":false,"given":"Mariana","family":"Garcia-Leal","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9433-5976","authenticated-orcid":false,"given":"Mayra A.","family":"Reyes-Soto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9597-8789","authenticated-orcid":false,"given":"Ivan","family":"Hernandez-Galarza","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5208-1429","authenticated-orcid":false,"given":"Neri A.","family":"Alvarez-Villalobos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9714-2109","authenticated-orcid":false,"given":"Dionicio A.","family":"Galarza-Delgado","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1181-4977","authenticated-orcid":false,"given":"Diana E.","family":"Flores-Alvarado","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,2,12]]},"reference":[{"key":"5622_CR1","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/0049-0172(73)90035-8","volume":"3","author":"JM Moll","year":"1973","unstructured":"Moll JM, Wright V (1973) Psoriatic arthritis. Semin Arthritis Rheum 3:55\u201378. https:\/\/doi.org\/10.1016\/0049-0172(73)90035-8","journal-title":"Semin Arthritis Rheum"},{"key":"5622_CR2","doi-asserted-by":"publisher","first-page":"65LP","DOI":"10.7861\/clinmedicine.17-1-65","volume":"17","author":"LC Coates","year":"2017","unstructured":"Coates LC, Helliwell PS (2017) Psoriatic arthritis: state of the art review. Clin Med 17:65LP\u201370LP. https:\/\/doi.org\/10.7861\/clinmedicine.17-1-65","journal-title":"Clin Med"},{"key":"5622_CR3","doi-asserted-by":"publisher","first-page":"ii14","DOI":"10.1136\/ard.2004.032482","volume":"64 Suppl2","author":"DD Gladman","year":"2005","unstructured":"Gladman DD, Antoni C, Mease P, Clegg DO, Nash P (2005) Psoriatic arthritis: epidemiology, clinical features, course, and outcome. Ann Rheum Dis 64 Suppl2:ii14\u2013ii17. https:\/\/doi.org\/10.1136\/ard.2004.032482","journal-title":"Ann Rheum Dis"},{"key":"5622_CR4","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1002\/1529-0131(200104)45:2<151::AID-ANR168>3.0.CO;2-T","volume":"45","author":"JA Husted","year":"2001","unstructured":"Husted JA, Gladman DD, Farewell VT, Cook RJ (2001) Health-related quality of life of patients with psoriatic arthritis: a comparison with patients with rheumatoid arthritis. Arthritis Rheum 45:151\u2013158. https:\/\/doi.org\/10.1002\/1529-0131(200104)45:2<151::AID-ANR168>3.0.CO;2-T","journal-title":"Arthritis Rheum"},{"key":"5622_CR5","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1007\/s40744-016-0029-z","volume":"3","author":"A Kavanaugh","year":"2016","unstructured":"Kavanaugh A, Helliwell P, Ritchlin CT (2016) Psoriatic arthritis and burden of disease: patient perspectives from the population-based multinational assessment of psoriasis and psoriatic arthritis (MAPP) Survey. Rheumatol Ther 3:91\u2013102. https:\/\/doi.org\/10.1007\/s40744-016-0029-z","journal-title":"Rheumatol Ther"},{"key":"5622_CR6","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1016\/j.semarthrit.2017.05.010","volume":"47","author":"ME Husni","year":"2017","unstructured":"Husni ME, Merola JF, Davin S (2017) The psychosocial burden of psoriatic arthritis. Semin Arthritis Rheum 47:351\u2013360. https:\/\/doi.org\/10.1016\/j.semarthrit.2017.05.010","journal-title":"Semin Arthritis Rheum"},{"key":"5622_CR7","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1016\/s0889-857x(05)70044-2","volume":"24","author":"DD Gladman","year":"1998","unstructured":"Gladman DD (1998) Psoriatic arthritis. Rheum Dis Clin N Am 24:829\u2013844. https:\/\/doi.org\/10.1016\/s0889-857x(05)70044-2","journal-title":"Rheum Dis Clin N Am"},{"key":"5622_CR8","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1111\/jdv.12163","volume":"27 Suppl 3","author":"C Horreau","year":"2013","unstructured":"Horreau C, Pouplard C, Brenaut E, Barnetche T, Misery L, Cribier B et al (2013) Cardiovascular morbidity and mortality in psoriasis and psoriatic arthritis: a systematic literature review. J Eur Acad Dermatol Venereol 27 Suppl 3:12\u201329. https:\/\/doi.org\/10.1111\/jdv.12163","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"5622_CR9","doi-asserted-by":"publisher","first-page":"2038","DOI":"10.1136\/annrheumdis-2017-211433","volume":"76","author":"A Kerschbaumer","year":"2017","unstructured":"Kerschbaumer A, Baker D, Smolen JS, Aletaha D (2017) The effects of structural damage on functional disability in psoriatic arthritis. Ann Rheum Dis 76:2038\u20132045. https:\/\/doi.org\/10.1136\/annrheumdis-2017-211433","journal-title":"Ann Rheum Dis"},{"key":"5622_CR10","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1186\/s13075-020-2103-8","volume":"22","author":"D van der Heijde","year":"2020","unstructured":"van der Heijde D, Gladman DD, Kavanaugh A, Mease P (2020) Assessing structural damage progression in psoriatic arthritis and its role as an outcome in research. Arthritis Res Ther 22:18. https:\/\/doi.org\/10.1186\/s13075-020-2103-8","journal-title":"Arthritis Res Ther"},{"key":"5622_CR11","doi-asserted-by":"publisher","first-page":"1060","DOI":"10.1002\/art.39573","volume":"68","author":"LC Coates","year":"2016","unstructured":"Coates LC, Kavanaugh A, Mease PJ, Soriano ER, Acosta-Felquer ML, Armstrong AW et al (2016) Group for research and assessment of psoriasis and psoriatic arthritis 2015 treatment recommendations for psoriatic arthritis. Arthritis Rheum 68:1060\u20131071. https:\/\/doi.org\/10.1002\/art.39573","journal-title":"Arthritis Rheum"},{"key":"5622_CR12","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1136\/annrheumdis-2015-208337","volume":"75","author":"L Gossec","year":"2016","unstructured":"Gossec L, Smolen JS, Ramiro S, de Wit M, Cutolo M, Dougados M, Emery P, Landew\u00e9 R, Oliver S, Aletaha D, Betteridge N, Braun J, Burmester G, Ca\u00f1ete JD, Damjanov N, FitzGerald O, Haglund E, Helliwell P, Kvien TK, Lories R, Luger T, Maccarone M, Marzo-Ortega H, McGonagle D, McInnes IB, Olivieri I, Pavelka K, Schett G, Sieper J, van den Bosch F, Veale DJ, Wollenhaupt J, Zink A, van der Heijde D (2016) European League Against Rheumatism (EULAR) recommendations for the management of psoriatic arthritis with pharmacological therapies: 2015 update. Ann Rheum Dis 75:499\u2013510. https:\/\/doi.org\/10.1136\/annrheumdis-2015-208337","journal-title":"Ann Rheum Dis"},{"key":"5622_CR13","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1136\/annrheumdis-2012-202641","volume":"73","author":"R Goulabchand","year":"2014","unstructured":"Goulabchand R, Mouterde G, Barnetche T, Lukas C, Morel J, Combe B (2014) Effect of tumour necrosis factor blockers on radiographic progression of psoriatic arthritis: a systematic review and meta-analysis of randomised controlled trials. Ann Rheum Dis 73:414\u2013419. https:\/\/doi.org\/10.1136\/annrheumdis-2012-202641","journal-title":"Ann Rheum Dis"},{"key":"5622_CR14","doi-asserted-by":"publisher","first-page":"2317","DOI":"10.1016\/S0140-6736(17)31429-0","volume":"389","author":"P Nash","year":"2017","unstructured":"Nash P, Kirkham B, Okada M, Rahman P, Combe B, Burmester GR, Adams DH, Kerr L, Lee C, Shuler CL, Genovese M, Ahmed K, Alper J, Barkham N, Bennett RE, Garc\u00eda FJB, Alonso RB, Blumstein HB, Brooks MS, Burmester GR, Cagnoli P, Caldron PH, Cantagrel A, Chen DY, Churchill MA Jr, Codding CE, Combe B, Deane PMG, del Giudice J, Deodhar AA, Dhar RK, Dokoupilova E, Egan RM, Everding A, Gal\u00edndez E, Genovese M, Goddard DH, Gottlieb A, Goupille P, Griffin RM, Gupta RC, Hall S, Hatti K, Howell MP, Huang YH, Jajoo R, Janssen NM, Kiltz U, Kivitz AJ, Klein SJ, Korkosz MP, Kotha R, Kremer JM, Lue C, de la Fuente JLM, Marzo-Ortega H, Masmitja JG, Mease PJ, Meroni PL, Mueller EC, Nandagudi AC, Nash P, Fern\u00e1ndez-Nebro A, Neuwelt CM, Orbai AM, Oza MR, Parks DL, Pattanaik D, Rell-Bakalarska ME, Rosmarin D, Roussou E, Rychlewska-Hanczewksa AI, Sikes DH, Stack MT, Sunkureddi P, Tahir H, Tha\u00e7i D, Tsai TF, Turkiewicz AM, Unger L, Cabello RV, Wagner U, Wei CC, Wells AF, Youssef P, Zielinska A (2017) Ixekizumab for the treatment of patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors: results from the 24-week randomised, double-blind, placebo-controlled period of the SPIRIT-P2 phase 3 trial. Lancet 389:2317\u20132327. https:\/\/doi.org\/10.1016\/S0140-6736(17)31429-0","journal-title":"Lancet"},{"key":"5622_CR15","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1136\/annrheumdis-2019-215386","volume":"79","author":"PJ Mease","year":"2020","unstructured":"Mease PJ, Smolen JS, Behrens F, Nash P, Liu Leage S, Li L, Tahir H, Gooderham M, Krishnan E, Liu-Seifert H, Emery P, Pillai SG, Helliwell PS, SPIRIT H2H study group (2020) A head-to-head comparison of the efficacy and safety of ixekizumab and adalimumab in biological-na\u00efve patients with active psoriatic arthritis: 24-week results of a randomised, open-label, blinded-assessor trial. Ann Rheum Dis 79:123\u2013131. https:\/\/doi.org\/10.1136\/annrheumdis-2019-215386","journal-title":"Ann Rheum Dis"},{"key":"5622_CR16","doi-asserted-by":"publisher","first-page":"e1000097","DOI":"10.1371\/journal.pmed.1000097","volume":"6","author":"D Moher","year":"2009","unstructured":"Moher D, Liberati A, Tetzlaff J, Altman DG (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med 6:e1000097. https:\/\/doi.org\/10.1371\/journal.pmed.1000097","journal-title":"PLoS Med"},{"key":"5622_CR17","doi-asserted-by":"publisher","first-page":"2665","DOI":"10.1002\/art.21972","volume":"54","author":"W Taylor","year":"2006","unstructured":"Taylor W, Gladman D, Helliwell P, Marchesoni A, Mease P, Mielants H (2006) Classification criteria for psoriatic arthritis: development of new criteria from a large international study. Arthritis Rheum 54:2665\u20132673. https:\/\/doi.org\/10.1002\/art.21972","journal-title":"Arthritis Rheum"},{"key":"5622_CR18","doi-asserted-by":"publisher","first-page":"1369LP","DOI":"10.1503\/cmaj.1031981","volume":"171","author":"T McGinn","year":"2004","unstructured":"McGinn T, Wyer PC, Newman TB, Keitz S, Leipzig R, Guyatt G (2004) Tips for learners of evidence-based medicine: 3. Measures of observer variability (kappa statistic). Can Med Assoc J 171:1369LP\u20131373LP. https:\/\/doi.org\/10.1503\/cmaj.1031981","journal-title":"Can Med Assoc J"},{"key":"5622_CR19","doi-asserted-by":"publisher","first-page":"l4898","DOI":"10.1136\/bmj.l4898","volume":"366","author":"JAC Sterne","year":"2019","unstructured":"Sterne JAC, Savovi\u0107 J, Page MJ, Elbers RG, Blencowe NS, Boutron I, Cates CJ, Cheng HY, Corbett MS, Eldridge SM, Emberson JR, Hern\u00e1n MA, Hopewell S, Hr\u00f3bjartsson A, Junqueira DR, J\u00fcni P, Kirkham JJ, Lasserson T, Li T, McAleenan A, Reeves BC, Shepperd S, Shrier I, Stewart LA, Tilling K, White IR, Whiting PF, Higgins JPT (2019) RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ 366:l4898. https:\/\/doi.org\/10.1136\/bmj.l4898","journal-title":"BMJ"},{"key":"5622_CR20","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1016\/j.jclinepi.2010.07.015","volume":"64","author":"H Balshem","year":"2011","unstructured":"Balshem H, Helfand M, Sch\u00fcnemann HJ, Oxman AD, Kunz R, Brozek J, Vist GE, Falck-Ytter Y, Meerpohl J, Norris S (2011) GRADE guidelines: 3. Rating the quality of evidence. J Clin Epidemiol 64:401\u2013406. https:\/\/doi.org\/10.1016\/j.jclinepi.2010.07.015","journal-title":"J Clin Epidemiol"},{"key":"5622_CR21","unstructured":"Higgins JPT, Li T, Deeks JJ (2020) Chapter 6: Choosing effect measures and computing estimates of effect. In: Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (eds) Cochrane Handbook for Systematic Reviews of Interventions version 6.1. Cochrane. Available from www.training.cochrane.org\/handbook. Accessed 10 Dec 2020"},{"key":"5622_CR22","unstructured":"Higgins JPT, Eldridge S, Li T (2020) Chapter 23: Including variants on randomized trials. In: Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (eds) Cochrane Handbook for Systematic Reviews of Interventions version 6.1 (updated September 2020). Cochrane. Available from www.training.cochrane.org\/handbook. Accessed 10 Dec 2020"},{"key":"5622_CR23","doi-asserted-by":"publisher","first-page":"2264","DOI":"10.1002\/art.20335","volume":"50","author":"PJ Mease","year":"2004","unstructured":"Mease PJ, Kivitz AJ, Burch FX, Siegel EL, Cohen SB, Ory P, Salonen D, Rubenstein J, Sharp JT, Tsuji W (2004) Etanercept treatment of psoriatic arthritis: safety, efficacy, and effect on disease progression. Arthritis Rheum 50:2264\u20132272. https:\/\/doi.org\/10.1002\/art.20335","journal-title":"Arthritis Rheum"},{"key":"5622_CR24","doi-asserted-by":"publisher","first-page":"3279","DOI":"10.1002\/art.21306","volume":"52","author":"PJ Mease","year":"2005","unstructured":"Mease PJ, Gladman DD, Ritchlin CT, Ruderman EM, Steinfeld SD, Choy EHS, Sharp JT, Ory PA, Perdok RJ, Weinberg MA, Adalimumab Effectiveness in Psoriatic Arthritis Trial Study Group (2005) Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: results of a double-blind, randomized, placebo-controlled trial. Arthritis Rheum 52:3279\u20133289. https:\/\/doi.org\/10.1002\/art.21306","journal-title":"Arthritis Rheum"},{"key":"5622_CR25","doi-asserted-by":"publisher","first-page":"79LP","DOI":"10.1136\/annrheumdis-2016-209709","volume":"76","author":"PJ Mease","year":"2017","unstructured":"Mease PJ, van der Heijde D, Ritchlin CT, Okada M, Cuchacovich RS, Shuler CL et al (2017) Ixekizumab, an interleukin-17A specific monoclonal antibody, for the treatment of biologic-naive patients with active psoriatic arthritis: results from the 24-week randomised, double-blind, placebo-controlled and active (adalimumab)-controlled period of the phase III trial SPIRIT-P1. Ann Rheum Dis 76:79LP\u201387LP. https:\/\/doi.org\/10.1136\/annrheumdis-2016-209709","journal-title":"Ann Rheum Dis"},{"key":"5622_CR26","doi-asserted-by":"publisher","first-page":"1537","DOI":"10.1056\/NEJMoa1615975","volume":"377","author":"P Mease","year":"2017","unstructured":"Mease P, Hall S, FitzGerald O, van der Heijde D, Merola JF, Avila-Zapata F, Cie\u015blak D, Graham D, Wang C, Menon S, Hendrikx T, Kanik KS (2017) Tofacitinib or Adalimumab versus Placebo for Psoriatic Arthritis. N Engl J Med 377:1537\u20131550. https:\/\/doi.org\/10.1056\/NEJMoa1615975","journal-title":"N Engl J Med"},{"key":"5622_CR27","doi-asserted-by":"publisher","first-page":"1550","DOI":"10.1136\/annrheumdis-2016-210724","volume":"76","author":"PJ Mease","year":"2017","unstructured":"Mease PJ, Gottlieb AB, van der Heijde D, FitzGerald O, Johnsen A, Nys M, Banerjee S, Gladman DD (2017) Efficacy and safety of abatacept, a T-cell modulator, in a randomised, double-blind, placebo-controlled, phase III study in psoriatic arthritis. Ann Rheum Dis 76:1550\u20131558. https:\/\/doi.org\/10.1136\/annrheumdis-2016-210724","journal-title":"Ann Rheum Dis"},{"key":"5622_CR28","doi-asserted-by":"publisher","first-page":"890","DOI":"10.1136\/annrheumdis-2017-212687","volume":"77","author":"P Mease","year":"2018","unstructured":"Mease P, van der Heijde D, Landew\u00e9 R, Mpofu S, Rahman P, Tahir H, Singhal A, Boettcher E, Navarra S, Meiser K, Readie A, Pricop L, Abrams K (2018) Secukinumab improves active psoriatic arthritis symptoms and inhibits radiographic progression: primary results from the randomised, double-blind, phase III FUTURE 5 study. Ann Rheum Dis 77:890\u2013897. https:\/\/doi.org\/10.1136\/annrheumdis-2017-212687","journal-title":"Ann Rheum Dis"},{"key":"5622_CR29","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1002\/art.20967","volume":"52","author":"CE Antoni","year":"2005","unstructured":"Antoni CE, Kavanaugh A, Kirkham B, Tutuncu Z, Burmester GR, Schneider U, Furst DE, Molitor J, Keystone E, Gladman D, Manger B, Wassenberg S, Weier R, Wallace DJ, Weisman MH, Kalden JR, Smolen J (2005) Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: results from the infliximab multinational psoriatic arthritis controlled trial (IMPACT). Arthritis Rheum 52:1227\u20131236. https:\/\/doi.org\/10.1002\/art.20967","journal-title":"Arthritis Rheum"},{"key":"5622_CR30","doi-asserted-by":"publisher","first-page":"1150","DOI":"10.1136\/ard.2004.032268","volume":"64","author":"C Antoni","year":"2005","unstructured":"Antoni C, Krueger GG, de Vlam K, Birbara C, Beutler A, Guzzo C, Zhou B, Dooley LT, Kavanaugh A, IMPACT 2 Trial Investigators (2005) Infliximab improves signs and symptoms of psoriatic arthritis: results of the IMPACT 2 trial. Ann Rheum Dis 64:1150\u20131157. https:\/\/doi.org\/10.1136\/ard.2004.032268","journal-title":"Ann Rheum Dis"},{"key":"5622_CR31","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1002\/art.24403","volume":"60","author":"A Kavanaugh","year":"2009","unstructured":"Kavanaugh A, McInnes I, Mease P, Krueger GG, Gladman DD, Gomez-Reino J, Papp K, Zrubek J, Mudivarthy S, Mack M, Visvanathan S, Beutler A (2009) Golimumab, a new human tumor necrosis factor alpha antibody, administered every four weeks as a subcutaneous injection in psoriatic arthritis: twenty-four-week efficacy and safety results of a randomized, placebo-controlled study. Arthritis Rheum 60:976\u2013986. https:\/\/doi.org\/10.1002\/art.24403","journal-title":"Arthritis Rheum"},{"key":"5622_CR32","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1016\/S0140-6736(13)60594-2","volume":"382","author":"IB McInnes","year":"2013","unstructured":"McInnes IB, Kavanaugh A, Gottlieb AB, Puig L, Rahman P, Ritchlin C et al (2013) Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trial. Lancet 382:780\u2013789. https:\/\/doi.org\/10.1016\/S0140-6736(13)60594-2","journal-title":"Lancet"},{"key":"5622_CR33","doi-asserted-by":"publisher","first-page":"990","DOI":"10.1136\/annrheumdis-2013-204655","volume":"73","author":"C Ritchlin","year":"2014","unstructured":"Ritchlin C, Rahman P, Kavanaugh A, McInnes IB, Puig L, Li S et al (2014) Efficacy and safety of the anti-IL-12\/23 p40 monoclonal antibody, ustekinumab, in patients with active psoriatic arthritis despite conventional non-biological and biological anti-tumour necrosis factor therapy: 6-month and 1-year results of the phase 3, multicentre, double-blind, placebo-controlled, randomised PSUMMIT 2 trial. Ann Rheum Dis 73:990\u2013999. https:\/\/doi.org\/10.1136\/annrheumdis-2013-204655","journal-title":"Ann Rheum Dis"},{"key":"5622_CR34","doi-asserted-by":"publisher","first-page":"48LP","DOI":"10.1136\/annrheumdis-2013-203696","volume":"73","author":"PJ Mease","year":"2014","unstructured":"Mease PJ, Fleischmann R, Deodhar AA, Wollenhaupt J, Khraishi M, Kielar D et al (2014) Effect of certolizumab pegol on signs and symptoms in patients with psoriatic arthritis: 24-week results of a Phase 3 double-blind randomised placebo-controlled study (RAPID-PsA). Ann Rheum Dis 73:48LP\u201355LP. https:\/\/doi.org\/10.1136\/annrheumdis-2013-203696","journal-title":"Ann Rheum Dis"},{"key":"5622_CR35","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1056\/NEJMoa1412679","volume":"373","author":"PJ Mease","year":"2015","unstructured":"Mease PJ, McInnes IB, Kirkham B, Kavanaugh A, Rahman P, van der Heijde D et al (2015) Secukinumab inhibition of interleukin-17A in patients with psoriatic arthritis. N Engl J Med 373:1329\u20131339. https:\/\/doi.org\/10.1056\/NEJMoa1412679","journal-title":"N Engl J Med"},{"key":"5622_CR36","doi-asserted-by":"publisher","first-page":"2151","DOI":"10.1002\/art.40226","volume":"69","author":"A Kavanaugh","year":"2017","unstructured":"Kavanaugh A, Husni ME, Harrison DD, Kim L, Lo KH, Leu JH, Hsia EC (2017) Safety and efficacy of intravenous golimumab in patients with active psoriatic arthritis: results through week twenty-four of the GO-VIBRANT study. Arthritis Rheum 69:2151\u20132161. https:\/\/doi.org\/10.1002\/art.40226","journal-title":"Arthritis Rheum"},{"key":"5622_CR37","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1136\/ard.2004.024463","volume":"64","author":"AD Fraser","year":"2005","unstructured":"Fraser AD, van Kuijk AWR, Westhovens R, Karim Z, Wakefield R, Gerards AH, Landew\u00e9 R, Steinfeld SD, Emery P, Dijkmans BA, Veale DJ (2005) A randomised, double blind, placebo controlled, multicentre trial of combination therapy with methotrexate plus ciclosporin in patients with active psoriatic arthritis. Ann Rheum Dis 64:859\u2013864. https:\/\/doi.org\/10.1136\/ard.2004.024463","journal-title":"Ann Rheum Dis"},{"key":"5622_CR38","doi-asserted-by":"publisher","first-page":"1112","DOI":"10.1002\/art.40851","volume":"71","author":"PJ Mease","year":"2019","unstructured":"Mease PJ, Gladman DD, Collier DH, Ritchlin CT, Helliwell PS, Liu L, Kricorian G, Chung JB (2019) Etanercept and methotrexate as monotherapy or in combination for psoriatic arthritis: primary results from a randomized, controlled phase III trial. Arthritis Rheumatol 71:1112\u20131124. https:\/\/doi.org\/10.1002\/art.40851","journal-title":"Arthritis Rheumatol"},{"issue":"suppl2","key":"5622_CR39","doi-asserted-by":"publisher","first-page":"ii61","DOI":"10.1136\/ard.2004.030809","volume":"64","author":"D van der Heijde","year":"2005","unstructured":"van der Heijde D, Sharp J, Wassenberg S, Gladman DD (2005) Psoriatic arthritis imaging: a review of scoring methods. Ann Rheum Dis 64(suppl2):ii61\u2013ii64. https:\/\/doi.org\/10.1136\/ard.2004.030809","journal-title":"Ann Rheum Dis"},{"key":"5622_CR40","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1186\/1477-7525-1-20","volume":"1","author":"B Bruce","year":"2003","unstructured":"Bruce B, Fries JF (2003) The Stanford health assessment questionnaire: dimensions and practical applications. Health Qual Life Outcomes 1:20. https:\/\/doi.org\/10.1186\/1477-7525-1-20","journal-title":"Health Qual Life Outcomes"},{"issue":"suppl 2","key":"5622_CR41","doi-asserted-by":"publisher","first-page":"ii49LP","DOI":"10.1136\/ard.2004.034165","volume":"64","author":"PJ Mease","year":"2005","unstructured":"Mease PJ, Antoni CE, Gladman DD, Taylor WJ (2005) Psoriatic arthritis assessment tools in clinical trials. Ann Rheum Dis 64(suppl 2):ii49LP\u2013iiii54. https:\/\/doi.org\/10.1136\/ard.2004.034165","journal-title":"Ann Rheum Dis"},{"issue":"suppl1","key":"5622_CR42","first-page":"391","volume":"63","author":"PJ Mease","year":"2004","unstructured":"Mease PJ, Ganguly R, Wanke L, Yu E, Singh A (2004) How much improvement in functional status is considered important by patients with active psoriatic arthritis: applying the Outcome Measures in Rheumatoid Arthritis Clinical Trials (OMERACT) group guidelines. Ann Rheum Dis 63(suppl1):391","journal-title":"Ann Rheum Dis"},{"key":"5622_CR43","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1136\/annrheumdis-2013-204858","volume":"74","author":"M Haroon","year":"2015","unstructured":"Haroon M, Gallagher P, FitzGerald O (2015) Diagnostic delay of more than 6 months contributes to poor radiographic and functional outcome in psoriatic arthritis. Ann Rheum Dis 74:1045\u20131050. https:\/\/doi.org\/10.1136\/annrheumdis-2013-204858","journal-title":"Ann Rheum Dis"},{"key":"5622_CR44","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1080\/1744666X.2018.1468252","volume":"14","author":"T Gudu","year":"2018","unstructured":"Gudu T, Gossec L (2018) Quality of life in psoriatic arthritis. Expert Rev Clin Immunol 14:405\u2013417. https:\/\/doi.org\/10.1080\/1744666X.2018.1468252","journal-title":"Expert Rev Clin Immunol"},{"key":"5622_CR45","unstructured":"Deeks JJ, Higgins JPT, Altman DG (2020) Chapter 10: analysing data and undertaking meta-analyses. In: Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (eds) Cochrane Handbook for Systematic Reviews of Interventions version 6.1. Cochrane. Available from www.training.cochrane.org\/handbook. Accessed 10 Dec 2020"},{"key":"5622_CR46","doi-asserted-by":"publisher","first-page":"CD012722","DOI":"10.1002\/14651858.CD012722.pub2","volume":"1","author":"TD Wilsdon","year":"2019","unstructured":"Wilsdon TD, Whittle SL, Thynne TRJ, Mangoni AA (2019) Methotrexate for psoriatic arthritis. Cochrane Database Syst Rev 1:CD012722. https:\/\/doi.org\/10.1002\/14651858.CD012722.pub2","journal-title":"Cochrane Database Syst Rev"},{"key":"5622_CR47","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1186\/s13075-016-1106-y","volume":"18","author":"RBM Landew\u00e9","year":"2016","unstructured":"Landew\u00e9 RBM, Connell CA, Bradley JD, Wilkinson B, Gruben D, Strengholt S, van der Heijde D (2016) Is radiographic progression in modern rheumatoid arthritis trials still a robust outcome? Experience from tofacitinib clinical trials. Arthritis Res Ther 18:212. https:\/\/doi.org\/10.1186\/s13075-016-1106-y","journal-title":"Arthritis Res Ther"},{"key":"5622_CR48","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/j.clim.2017.07.022","volume":"186","author":"D van der Heijde","year":"2018","unstructured":"van der Heijde D, Landew\u00e9 R (2018) Should radiographic progression still be used as outcome in RA? Clin Immunol 186:79\u201381. https:\/\/doi.org\/10.1016\/j.clim.2017.07.022","journal-title":"Clin Immunol"}],"container-title":["Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-021-05622-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10067-021-05622-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-021-05622-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,11]],"date-time":"2021-08-11T09:09:05Z","timestamp":1628672945000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10067-021-05622-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,12]]},"references-count":48,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2021,9]]}},"alternative-id":["5622"],"URL":"https:\/\/doi.org\/10.1007\/s10067-021-05622-w","relation":{},"ISSN":["0770-3198","1434-9949"],"issn-type":[{"type":"print","value":"0770-3198"},{"type":"electronic","value":"1434-9949"}],"subject":[],"published":{"date-parts":[[2021,2,12]]},"assertion":[{"value":"11 December 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 January 2021","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 January 2021","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 February 2021","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The manuscript does not contain clinical studies or patient data.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical standards"}},{"value":"None.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosures"}}]}}